News

Alnylam Pharmaceuticals, Inc., the leading RNAi therapeutics company, today announced the U.S. Food and Drug Administration (FDA) approval of the supplemental New Drug Application…
Read More...

Servier, an independent global pharmaceutical group governed by a non-profit foundation, and Black Diamond Therapeutics, Inc., a clinical-stage oncology company developing MasterKey…
Read More...

The Menarini Group ("Menarini"), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. ("Stemline"), a wholly-owned subsidiary of the Menarini…
Read More...

Novartis today announced that oral Fabhalta (iptacopan) has received U.S. Food and Drug Administration (FDA) approval for the treatment of adults with C3 glomerulopathy (C3G), to reduce…
Read More...

Altesa BioSciences, Inc., a clinical-stage pharmaceutical company dedicated to developing new treatments for viral infections in vulnerable populations, announced that the U.S. Food and…
Read More...

Oxford BioTherapeutics (OBT), a clinical stage oncology company with a pipeline of immuno-oncology (IO) and Antibody Drug Conjugate (ADC)-based therapies, announced a multi-year…
Read More...

OPKO Health, Inc. and Entera Bio Ltd., a leader in the development of oral peptides and proteins replacement therapies, entered into a collaboration and license agreement to advance…
Read More...

Salipro Biotech AB, a Swedish biotech company specialising in the stabilisation of challenging drug targets, announced a research and license agreement with Boehringer Ingelheim to…
Read More...

AstraZeneca and Alteogen Inc. have entered into an exclusive license agreement for ALT-B4, a novel hyaluronidase utilising Hybrozyme platform technology. Under the terms of the…
Read More...

AstraZeneca has entered into a definitive agreement to acquire EsoBiotec, a biotechnology company pioneering in vivo cell therapies that has demonstrated promising early clinical…
Read More...

Bristol Myers Squibb announced that the European Commission (EC) has granted approval to Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T…
Read More...

Latigo Biotherapeutics ("Latigo"), a clinical-stage biotechnology company developing best-in-class non-opioid pain treatments that target pain at its source, announced it has closed…
Read More...

Azurity Pharmaceuticals announced the successful completion of its acquisition of Covis Group S.à r.l. (“Covis”) from existing investors. With this acquisition, Covis is now a…
Read More...

Zealand Pharma A/S, a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announces a global collaboration and license agreement with…
Read More...

Merck, known as MSD outside of the United States and Canada, announced the presentation of positive results from two pivotal Phase 3 trials of the investigational, once-daily, oral,…
Read More...

Vivace Therapeutics, Inc., a small molecule discovery and development company developing first-in-class cancer therapies targeting the Hippo pathway, announced the closing of a $35…
Read More...

Emergent BioSolutions Inc., a leading public health company that delivers protective and life-saving solutions to communities across the world, and Rocketvax Ltd, one of Switzerland’s…
Read More...

ElevateBio, a technology-driven company focused on powering the creation of life-transforming genetic medicines, announced a multi-year collaboration with Amazon Web Services (AWS) to…
Read More...

The Ministry of Health, Labor, and Welfare (MHLW) in Japan has granted Orphan Drug Designation (ODD) to Lundbeck's investigational drug, amlenetug, a potential new treatment option…
Read More...

Ionis Pharmaceuticals, Inc. announced that Ionis and AstraZeneca’s WAINZUA (eplontersen) has been approved in the European Union (EU) for the treatment of hereditary…
Read More...